Biotech for bees

One Miami startup hopes to cure a mysterious plague threatening the food supply.

EMAIL  |   PRINT  |   SHARE  |   RSS
 
google my aol my msn my yahoo! netvibes
Paste this link into your favorite RSS desktop reader
See all CNNMoney.com RSS FEEDS (close)

bee_pollen.ce.03.jpg
Photos
Next Little Thing 2009 Next Little Thing 2009 Next Little Thing 2009
Each year Fortune Small Business celebrates entrepreneurs whose cutting-edge ideas will keep us talking for the next 12 months. Check out this year's crop of flying cars, blimp power and GPS-enhanced cows.

(Fortune Small Business) -- Bee colonies might not seem like the most lucrative market for designer drugs. But the need is urgent: CCD, or colony collapse disorder, a strange syndrome that kills adult worker bees outside the hive, has been reported across the U.S. and Europe. The U.S. Department of Agriculture (USDA) says American beekeepers lost 37% of their hives to CCD last year, after losing 31% the year before.

Scientists still can't agree on which virus, if any, causes CCD. The government estimates that a third of our food supply - $15 billion annually in vegetables, nuts and fruits from plants that depend on bees for pollination - could be in danger.

Enter Beeologics, a Miami biotech startup that aims to create vaccines for all viruses that could lead to CCD. It's an unlikely collaboration between Eyal Ben-Chanoch, 49, a tech entrepreneur who helped design the first Intel (INTC, Fortune 500) Pentium chip, and Ilan Sela, 71, an Israeli expert on sequencing the genomes of bee viruses.

The pair saw a crisis no other company was responding to and gathered 10 top researchers to work on a cure.

"There hasn't been a lot of support for bee health," says Ben-Chanoch. "Our mission is to fill that void." The company's first proprietary vaccine, Remebee, is in trials with six beekeepers. (Poking insects with syringes is tricky, so the drug is added to a sucrose solution used to feed bees.)

FDA approval is still pending, but the company is confident it will be able to commercialize the vaccine this summer, at around $2 per dose. A hive will need one dose per month. Multiply that by the nation's 2.5 million remaining hives, and Beeologics could soon be buzzing with revenues.

Jeff Pettis, head of the USDA's Bee Research Laboratory, is cautiously enthusiastic about Remebee's potential. CCD likely stems from multiple factors, he says, some of which have yet to be discovered. But with time running out before the food chain is affected, any cure is worth trying.

"We live in a land of milk and honey," says Pettis, "but the honey can no longer be taken for granted."  To top of page

To write a note to the editor about this article, click here.




QMy dream is to launch my own business someday. Now that it's time to choose a major, I'm debating if I should major in entrepreneurial studies or major in engineering to acquire a set of skills first. Is majoring in entrepreneurship a good choice? More
Get Answer
- Spate, Orange, Calif.

Sponsors
More Galleries
6 great Memorial Day car deals Here are some hot tips if you're going out car-shopping this weekend. More
10 multi-million-dollar mega-yachts These folks definitely do not need a bigger boat. Peek inside some of the swankiest vessels on the high seas. More
Build your own eco-friendly house Home is wherever you want it to be. This 150-square-foot home can be shipped almost anywhere and then assembled like Ikea furniture in about four days. More
Worry about the hackers you don't know 
Crime syndicates and government organizations pose a much greater cyber threat than renegade hacker groups like Anonymous. Play
GE CEO: Bringing jobs back to the U.S. 
Jeff Immelt says the U.S. is a cost competitive market for advanced manufacturing and that GE is bringing jobs back from Mexico. Play
Hamster wheel and wedgie-powered transit 
Red Bull Creation challenges hackers and engineers to invent new modes of transportation. Play

Market indexes are shown in real time, except for the DJIA, which is delayed by two minutes. All times are ET. Disclaimer LIBOR Warning: Neither BBA Enterprises Limited, nor the BBA LIBOR Contributor Banks, nor Reuters, can be held liable for any irregularity or inaccuracy of BBA LIBOR. Disclaimer. Morningstar: © 2012 Morningstar, Inc. All Rights Reserved. Disclaimer The Dow Jones IndexesSM are proprietary to and distributed by Dow Jones & Company, Inc. and have been licensed for use. All content of the Dow Jones IndexesSM © 2012 is proprietary to Dow Jones & Company, Inc. Chicago Mercantile Association. The market data is the property of Chicago Mercantile Exchange Inc. and its licensors. All rights reserved. FactSet Research Systems Inc. 2012. All rights reserved. Most stock quote data provided by BATS.